JP2011518816A5 - - Google Patents

Download PDF

Info

Publication number
JP2011518816A5
JP2011518816A5 JP2011505583A JP2011505583A JP2011518816A5 JP 2011518816 A5 JP2011518816 A5 JP 2011518816A5 JP 2011505583 A JP2011505583 A JP 2011505583A JP 2011505583 A JP2011505583 A JP 2011505583A JP 2011518816 A5 JP2011518816 A5 JP 2011518816A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
optionally substituted
group
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011505583A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011518816A (ja
Filing date
Publication date
Priority claimed from GBGB0807451.0A external-priority patent/GB0807451D0/en
Application filed filed Critical
Publication of JP2011518816A publication Critical patent/JP2011518816A/ja
Publication of JP2011518816A5 publication Critical patent/JP2011518816A5/ja
Withdrawn legal-status Critical Current

Links

JP2011505583A 2008-04-24 2009-04-23 Plkインヒビター Withdrawn JP2011518816A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0807451.0A GB0807451D0 (en) 2008-04-24 2008-04-24 Inhibitors of PLK
GB0807451.0 2008-04-24
PCT/GB2009/001019 WO2009130453A1 (en) 2008-04-24 2009-04-23 Inhibitors of plk

Publications (2)

Publication Number Publication Date
JP2011518816A JP2011518816A (ja) 2011-06-30
JP2011518816A5 true JP2011518816A5 (enExample) 2012-05-31

Family

ID=39494145

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011505583A Withdrawn JP2011518816A (ja) 2008-04-24 2009-04-23 Plkインヒビター

Country Status (5)

Country Link
US (1) US20110190306A1 (enExample)
EP (1) EP2296662A1 (enExample)
JP (1) JP2011518816A (enExample)
GB (1) GB0807451D0 (enExample)
WO (1) WO2009130453A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0803747D0 (en) * 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
CN102762568A (zh) * 2009-12-23 2012-10-31 伊兰药品公司 作为polo样激酶的抑制剂的蝶啶酮
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
SI3222616T1 (sl) 2012-10-17 2019-10-30 Macrophage Pharma Ltd N-(2-(4-(6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2H)-IL)-3,5- difluorofenil)etil)-L-alanin in njegov terbutil ester
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021548A1 (de) * 2004-08-27 2006-03-02 Boehringer Ingelheim International Gmbh Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
BRPI0718120A2 (pt) * 2006-10-25 2013-11-12 Chroma Therapeutics Ltd Derivados de pteridina como inibidores de cinase do tipo pólo úteis no tratamento de câncer

Similar Documents

Publication Publication Date Title
JP2011513288A5 (enExample)
JP2010507639A5 (enExample)
JP2013523897A5 (enExample)
JP2010505802A5 (enExample)
NO303337B1 (no) Forbindelser med ›3-agonistaktivitet, farmas÷ytisk preparat pÕ basis derav og mellomprodukter for fremstilling av forbindelsene
JP2014515406A5 (enExample)
JP2011513305A5 (enExample)
JP2013531008A5 (enExample)
JP2008540389A5 (enExample)
RU97118591A (ru) Производные ацетамида, способ его получения и содержащие его фармацевтические композиции
JP2011527334A5 (enExample)
JP2011509949A5 (enExample)
JP2012523457A5 (enExample)
RU2012155118A (ru) Способы лечения биполярного расстройства
RU2008136072A (ru) Производные бензамидов и гетероаренов
RU2012123154A (ru) Способы лечения синдрома фибромиалгии
JP2013533253A5 (enExample)
RU2006137079A (ru) Производные а-аминоамида, полезные при лечении синдрома усталых ног и вызывающих привыкание расстройств
CA2780224A1 (en) Use of benzo-heterocycle derivatives for preventing and treating cancer or for inhibiting cancer metastasis
RU2005133994A (ru) Оксимные производные и их применение в качестве фармацевтически активных агентов
JP2012508249A5 (enExample)
JP2010508336A5 (enExample)
JP2011523952A5 (enExample)
JP2013542980A5 (enExample)
JP2014500265A5 (enExample)